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Leukopenia is common following renal transplantation, though it is infrequently 
reported and lacks well-defined management. We retrospectively reviewed 228 
consecutive renal transplant recipients at a single center for leukopenia in the 
first year following transplant. Leukopenic patients were evaluated for treatment 
strategies, efficacy, and complications including CMV infection, rejection, graft 
failure, and death. Leukopenia was observed in 43 of 228 (19%) transplants with 
median onset and duration of 95 days. Ninety-three percent of patients received 
treatment for leukopenia including Neupogen®, dose reduction of mycophenolic 
acid (MPA) or valganciclovir, and initiation of prednisone. Grade 2 neutropenia, 
defined as ANC≤1000 cells/mm3, had statistically significant increased incidence of 
CMV (p<0.0001), defined as positive serum PCR, and rejection (p=0.013) compared 
to non-leukopenic patients.  MPA dose reductions >50% were associated with 
higher rates of both CMV (60% v 42%) and rejection (60% v 33%). Conclusions: 1. 
Leukopenic patients experience significantly increased CMV and rejection. 2. MPA 
and valganciclovir dose reductions are associated with increased risk of rejection 
and CMV. 3. Neupogen® is an effective treatment for leukopenia.
Conclusions: 
 1.	 	Leukopenic patients experience significantly increased CMV and rejection. 
	 2.	 	MPA and valganciclovir dose reductions are associated with an increased risk of 
rejection and CMV.
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Background: 
While lymphocyte depleting induction immunosuppression agents are responsible for 
much of the early post-transplant leukopenia, MPA and valganciclovir have also been 
linked to a decrease in WBC count and ANC.1-3
Methods: 
This retrospective, single-center study included all patients undergoing kidney and/or 
pancreas transplantation between January 2009 and May 2012. All recipients received 
thymoglobulin 4-6mg/kg in 3-4 doses and maintenance MPA/tacrolimus. All leukopenic 
episodes occurring between one month and one year post-transplant were analyzed. 
Successful treatment of leukopenia was defined as a WBC count of greater than 3500 








































Leukopenic patients had significantly lower BMI (p=0.0152) than non-leukopenic 
patients, but matched in age, gender, transplant type, and PRA.  Interventions for 
leukopenia were not standardized.
Severely neutropenic patients had a statistically significant increased incidence of 
CMV (p<0.0001) compared with non-leukopenic patients.  Of the 20 leukopenic 
patients who developed CMV, 10/20 (50%) developed CMV prior to leukopenia.  
Compared with full dose valganciclovir, dose reduction was associated with a higher 
rate of CMV (77% v 37%) p=0.021.  Only 4 of 10 had dose reduction prior to the CMV 
infection.  
Neutropenic patients also had a statistically significant increase in rejection 
(p=0.013) compared with non-leukopenic patients.  11/17 (65%) leukopenic patients 
experienced rejection after treatment of leukopenia. 
While greater degrees of MPA dose reduction resulted in a shorter median duration of 
leukopenia  (110 v 74 days), greater MPA dose reductions were also associated with 
higher rates of CMV and rejection (see graph).  
Grade 1 Neutropenia (1000 cells/mm3<ANC≤1500 cells/mm3), and Grade 2 Neutropenia 
(ANC≤1000 cells/mm3). 
Of the 4 patients who received Neupogen® without any medication dose reductions, 
only 1 experienced rejection and CMV. Neupogen® took the shortest amount of time to 
recover WBC count (29 days) compared to prednisone (71 days), MPA dose reductions 
(55 days), and valganciclovir dose reduction (35 days). It is difficult to attribute 
improvement in leukopenia to one treatment given the multifactorial treatment 
process.
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